![Christy Oliger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christy Oliger
Direktor/Vorstandsmitglied bei
KARYOPHARM THERAPEUTICS INC.
Vermögen: 106 098 $ am 31.05.2026
Profil
Christy J.
Oliger currently serves as Independent Director at Nuvalent, Inc. since 2025, Karyopharm Therapeutics, Inc. since 2020, Replimune Group, Inc. since 2021, and Vera Therapeutics, Inc. since 2024.
Former roles include Independent Director at Sierra Oncology, Inc. from 2021 to 2022, Independent Director at Reata Pharmaceuticals, Inc. from 2021 to 2023, Director at Rayzebio, Inc. from 2023 to 2024, Independent Non-Executive Director at LAVA Therapeutics NV from 2023 to 2025, and Senior Vice President-Oncology Business Unit at Genentech, Inc. from 2017 to 2020.
Education includes undergraduate studies at the University of California, Santa Barbara.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2026 | 2.987 ( 0 % ) | 106 098 $ | 31.05.2026 | |
| 01.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 | |
| 31.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 | |
| 21.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Christy Oliger
| Unternehmen | Position | Beginn |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 28.08.2020 |
| REPLIMUNE GROUP, INC. | Direktor/Vorstandsmitglied | 01.12.2021 |
| VERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 07.06.2024 |
| NUVALENT, INC. | Direktor/Vorstandsmitglied | 18.06.2025 |
Ehemalige bekannte Positionen von Christy Oliger
| Unternehmen | Position | Ende |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Direktor/Vorstandsmitglied | 07.11.2025 |
| RAYZEBIO, INC. | Direktor/Vorstandsmitglied | 26.02.2024 |
| REATA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.06.2023 |
| SIERRA ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 01.07.2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01.07.2020 |
Ausbildung von Christy Oliger
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
95
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
